PCAS  a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales for the first half of 2017. The PCAS Group had generated consolidated net sales of €110.2 million in the first half of 2017, representing growth of +9.4% compared to the same period during the previous financial year (+9.1% at a constant exchange rate).

Pharmaceutical Synthesis

The Pharmaceutical Synthesis business generated €75.8 million, up +10.5% on 2016 (+10.5% at a constant exchange rate), which was especially driven by the Exclusive activity.

Fine Specialty Chemicals

Net sales of Fine Specialty Chemicals totaled €34.4 million, up 7.1% on 2016 (+6.2% at a constant exchange rate), with growth in both Performance Additives and Advanced Specialty Chemicals for micro-electronic chemicals.

Outlook for the current year

The company has confirmed its growth targets for net sales in 2017 and for all its lines of business.